Chronopharmacological studies on potassium citrate treatment of oxalocalcic urolithiasis

Grases, F.; Conte, Antonio Hernandez; March, J.G.; García-Ferragut, L.; Villalonga, Núria

doi:10.1007/bf02550921

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with this observation the SEM‐EDX analysis revealed that there were no crystal depositions in the tubular lumens of the astaxanthin‐treated nephrolithiatic group, indicating the ability of astaxanthin to disrupt crystal formation. Citrate therapy has been used for a long time in the clinical management of kidney stones . In the present study, we found that the renal tissue of citrate‐treated rats had high calcium content with some stray crystal deposits as opposed to the astaxanthin‐treated group, which had a normal histology and calcium levels.…”

Section: Discussionsupporting

confidence: 46%

“…Therefore, we investigated the effect of astaxanthin treatment on the correlations of ACE levels with renal OPN and TGF‐β1 expressions and calcium oxalate deposition in male Wistar rats. Oral potassium citrate intake is a common strategy for treatment of renal calculi . A comparison was made to evaluate the efficacy of astaxanthin treatment over potassium citrate administration on renal stone formation and regulation of OPN and TGF‐β1 expressions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Astaxanthin modulates osteopontin and transforming growth factor β1 expression levels in a rat model of nephrolithiasis: a comparison with citrate administration

et al. 2014

View full text Add to dashboard Cite

Objectives• To evaluate the effect of astaxanthin on renal angiotensin-I converting enzyme (ACE) levels, osteopontin (OPN) and transforming growth factor β1 (TGF-β1) expressions and the extent of crystal deposition in experimentally induced calcium oxalate kidney stone disease in a male Wistar rat model.• To compare the efficacy of astaxanthin treatment with a currently used treatment strategy (citrate administration) for kidney stones. Materials and Methods• The expression of OPN was assessed by immunohistochemistry. One step reverse transcriptase polymerase chain reaction followed by densitometry was used to assess renal OPN and TGF-β1 levels.• Renal ACE levels were quantified by an enzyme-linked immunosorbent assay method.• Crystal deposition in kidney was analysed by scanning electron microscopic (SEM)-energy-dispersive X-ray (EDX). Results• The renal ACE levels and the expression of OPN and TGF-β1 were upregulated in the nephrolithiasis-induced rats.• Astaxanthin treatment reduced renal ACE levels and the expression OPN and TGF-β1.• SEM-EDX analysis showed that crystal deposition was reduced in the astaxanthin-treated nephrolithiatic group. • Astaxanthin treatment was more effective than citrate administration in the regulation of renal ACE levels, OPN and TGF-β1 expressions. Conclusions• Astaxanthin administration reduced renal calcium oxalate crystal deposition possibly by modulating the renal renin-angiotensin system (RAS), which reduced the expression of OPN and TGF-β1 levels.• Astaxanthin administration was more effective than citrate treatment in reducing crystal deposition and down-regulating the expression of OPN and TGF-β1.

show abstract

Section: Discussionsupporting

confidence: 46%

Section: Introductionmentioning

confidence: 99%